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Abstract. 
 
An insulin-containing fusion protein (ICFP,
 
encoding the yeast prepro-
 
 
 
 factor leader peptide fused
via a lysine-arginine cleavage site to a single chain insu-
 
lin) has been expressed in 
 
Saccharomyces cerevisiae
 
where it is inefﬁciently secreted. Single gene disruptions
have been identiﬁed that cause enhanced immunoreac-
 
tive insulin secretion (
 
eis
 
). Five out of six 
 
eis
 
 mutants
 
prove to be vacuolar protein sorting (
 
vps
 
)
 
8
 
, 
 
vps35
 
,
 
vps13
 
, 
 
vps4
 
, and 
 
vps36
 
, which affect Golgi
 
↔
 
endosome
trafﬁcking. Indeed, in wild-type yeast insulin is ulti-
mately delivered to the vacuole, whereas 
 
vps
 
 mutants
secrete primarily unprocessed ICFP. Disruption of
 
KEX2
 
, which blocks intracellular processing to insulin,
 
quantitatively reroutes ICFP to the cell surface, whereas
loss of the Vps10p sorting receptor is without effect. Se-
cretion of unprocessed ICFP is not based on a domi-
 
nant secretion signal in the 
 
 
 
-leader peptide. Although
insulin sorting mediated by Kex2p is saturable, Kex2p
functions not as a sorting receptor but as a protease: re-
placement of Kex2p by truncated secretory Kex2p
(which travels from Golgi to cell surface) still causes
endoproteolytic processing and intracellular insulin re-
tention. Endoproteolysis promotes a change in insulin’s
biophysical properties. B5His residues normally partici-
pate in multimeric insulin packing; a point mutation at
this position permits ICFP processing but causes the
majority of processed insulin to be secreted. The data
argue that multimeric assembly consequent to endopro-
teolytic maturation regulates insulin sorting in the secre-
tory pathway.
Key words: multimerization • assembly • secretory
protein • trafﬁcking • sorting by retention
 
Introduction
 
We are interested in better understanding the principles
governing insulin trafficking in the eukaryotic secretory
pathway. In this study, we have employed heterologous
 
protein expression in the yeast, 
 
Saccharomyces cerevisiae
 
.
One might imagine that a confounding factor in this system
would be the absence of specialized processing enzymes,
 
PC1 and PC2, that higher eukaryotes normally employ for
endoproteolytic processing to insulin from its protein pre-
cursor (Steiner, 1998). However, this problem is circum-
vented by the synthesis of a chimeric protein in which the
 
signal peptide and leader sequence of yeast prepro-
 
 
 
 fac-
tor is fused (via a single dibasic site that is recognized and
processed by the Kex2p endoprotease, which acts in the
yeast Golgi complex [Fuller et al., 1989]) to a single chain
insulin (comprised of insulin B and A chains that are con-
tiguous, linked by a short noncleaved peptide). Upon en-
doproteolytic cleavage to liberate the 
 
 
 
-leader peptide, a
crystallizable insulin is produced with a structure essen-
tially isomorphous with that of authentic two-chain insulin
(Thim et al., 1986; Hua et al., 1998; Kjeldsen et al., 1998).
 
Despite this, various insulin and/or insulin-like growth
factor–containing constructs have been found to be secreted
inefficiently from yeast (Steube et al., 1991; Kjeldsen et al.,
1997); these constructs are apparently subject to quality con-
trol in the secretory pathway. Indeed, the poor secretion of a
 
variety of heterologous secretory proteins from 
 
S. cerevisiae
 
is generally attributed to the recognition and retention of
 
these proteins in the endoplasmic reticulum (ER)
 
1
 
 (Kowal-
ski et al., 1998), typically via binding of ER molecular chap-
erones (Ellgaard et al., 1999). Accumulated proteins that do
not satisfy quality control requirements for export are gen-
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erally degraded by ER-associated degradation (ERAD)
(Brodsky and McCraken, 1997; Kopito, 1997).
By contrast, studies of insulin storage in the regulated
secretory pathway of mammalian cells generally support a
model known as “sorting by retention” (Kuliawat and Ar-
van, 1994). The model suggests that endoproteolytic pro-
cessing of the insulin precursor, resulting in polymeric as-
sembly of the processed insulin product (Huang and
Arvan, 1995), prevents its rapid (constitutive-like) secre-
tion and facilitates its intracellular retention (Arvan and
Castle, 1998). Recently, by introducing the PC1 cDNA
into regulated secretory cells that do not normally express
this endoprotease, we found that conversion to insulin (by
endoproteolysis) improves the efficiency of intracellular
hormone storage. Specifically, to the extent that the insu-
lin precursor remains unprocessed it is very rapidly se-
creted, whereas the fraction effectively processed to insu-
lin is retained intracellularly with remarkable efficiency
(Kuliawat et al., 2000). Based on these findings and the ex-
istence of detailed structural information (Dodson and
Steiner, 1998), insulin seemed like a suitable substrate for
further studies of quality control and sorting in 
 
S. cerevi-
siae
 
 (an organism particularly amenable to such studies)
(Gillece et al., 1999; Wang and Chang, 1999). In particular,
we have been interested to learn if the reportedly ineffi-
cient insulin secretion occurs primarily in relation to ER
quality control events or perhaps in relation to processing
or other events that take place more distally in the secre-
tory pathway.
Here, we describe an insulin-containing fusion protein
(ICFP) that is secreted inefficiently from 
 
S. cerevisiae
 
.
However, instead of ERAD we find that the single chain
insulin is sorted in the Golgi complex and is retained intra-
cellularly and eventually degraded within the endosomal/
vacuolar system. Remarkably, we find that this sorting re-
quires 
 
KEX2
 
 and is dependent on endoproteolytic process-
ing to form mature insulin; either loss of this cleavage or a
point mutation that is known to affect the nature of insulin
crystal packing causes dramatically augmented secretion of
ICFP or insulin, respectively. These data appear consistent
with a model in which insulin’s biophysical properties par-
ticipate in its sorting in the secretory pathway.
 
Materials and Methods
 
Strains
 
The strains employed in this study are described in Table I. Strain L5145
(
 
MATa
 
,
 
 kss1
 
,
 
 ura3-52
 
,
 
 leu2-3,112
 
,
 
 his3
 
,
 
 trp1^63
 
,
 
 ade2
 
,
 
 GAL
 
 
 
) and L5141
that is MAT
 
 
 
 but otherwise isogenic to L5145 (from the lab of G. Fink,
Whitehead Institute, Boston, MA). Unless stated otherwise, all strains
used in this study are isogenic to L5145. To construct the 
 
pep4
 
 
 
 strain
called PA13 (Table I), a deletion construct marked with 
 
hisG-URA3-hisG
 
(pAS173 cut with EcoRI and XhoI) was used for transformation (Chang
and Fink, 1995). Pop out of the 
 
URA3
 
 marker was obtained by selection
on 5-FOA (Boeke et al., 1987). 
 
pep4
 
 
 
 was confirmed phenotypically by
loss of carboxypeptidase Y (CPY) processing to the mature form. A strain
(L5145/pMI316) expressing ICFP from a single chromosomal locus was
generated by transformation of L5145 with a yeast integration plasmid
(pRS304) bearing 
 
GAL1-ICFP
 
; the plasmid was linearized with Stu1 for
integration at 
 
ura3
 
. A 
 
kex2
 
 
 
 strain was generated by transformation with
a BamHI fragment from pKX::HIS3-(S) (Redding et al., 1991). A 
 
vps1
 
 
 
::
LEU2
 
 strain was obtained by transformation with pCRK3A (Rothman et
al., 1990). A 
 
vps10
 
 strain was obtained by transformation with XhoI and
BamHI fragment of pEM10-103 (Marcusson et al., 1994).
 
Plasmids and Molecular Biology
 
pAK966 is a 2-
 
 
 
 plasmid marked with 
 
URA3
 
 in which the 
 
GAL1 
 
promoter
controls expression of ICFP inserted between the EcoRI and XbaI sites of
pYES2 (Invitrogen). pMI306 and pMIGLC are 
 
TRP1
 
-marked centromeric
plasmids (pRS314; Sikorski and Hieter, 1989) bearing ICFP driven by the
 
GAL1
 
 or 
 
GPD1
 
 promoter, respectively. pMI306 was created by excising
an 
 
 
 
1-kB XbaI-SpeI fragment (containing 
 
GAL1-ICFP
 
) from pAK966
and subcloning it into the SpeI site of pRS314. pMI316 was created by ex-
cising an 
 
 
 
1-kB SalI-NotI fragment (containing 
 
GAL1-ICFP
 
) from
pMI306 and subcloning it into the respective sites of pRS304 marked with
 
URA3
 
 (Sikorski and Hieter, 1989). pMIGLC was created by excising an
 
 
 
0.6-kB BamHI-XbaI fragment from pAK966 and subcloning it into the
respective sites of pUC19 and then excising an 
 
 
 
0.6-kB BamHI-SalI frag-
ment from the resulting plasmid and subcloning it into the respective sites
of pRSGLC, a 
 
TRP1
 
-marked centromeric plasmid that employs the 
 
GPD1
 
promoter (from Dr. J. Warner, Albert Einstein College of Medicine)
(Warner, 1991). pASZ-SL-GM was created by excising an 
 
 
 
1-kb XbaI
fragment (containing 
 
GAL1-ICFP
 
) from the commercial pSL1180 shuttle
vector (Amersham Pharmacia Biotech) and subcloning it into pASZ11, an
 
ADE2
 
-marked centromeric plasmid (Stotz and Linder, 1990). pHSP150
 
frag
 
-
insulin was constructed as follows. Single chain insulin was amplified from
pAK966 by PCR using two primers: TATCCATGGCTGCAGCCAA-
GAGATTCGTTAACCAACAC (which introduces a PstI site, under-
lined) and GTCGACTCTAGAGCCTGCGG (which introduces an XbaI
site, underlined). After digestion with PstI and XbaI, the 
 
 
 
200-bp PCR
product was subcloned into pSL1180 (Amersham Pharmacia Biotech) and
then excised at PstI and ClaI and subcloned again into the respective sites
of pKTH4536 (from Dr. M. Makarow, University of Helsinki, Helsinki,
Finland) (Simonen et al., 1994). The resulting plasmid contains the
 
HSP150
 
 promoter and encodes the HSP150 signal and a portion of the
leader peptide up to amino acid 63, linked via KR to single chain insulin;
the 3
 
 
 
 ClaI site immediately precedes the alcohol dehydrogenase termina-
tor. An 
 
 
 
3-kb fragment containing all of these regions was excised by
BamHI and finally cloned into the BamHI site of pRS315, a 
 
LEU2-
 
marked
centromeric plasmid (Sikorski and Hieter, 1989). pKX::HIS3-S(yn), a plas-
mid for complete gene replacement of 
 
KEX2
 
 with 
 
HIS3
 
 (
 
kex2
 
 
 
2
 
::HIS3-S
 
),
and pAB23, a 
 
URA3-
 
marked 2-
 
 
 
 plasmid in which the 
 
TDH3
 
 promoter
drives the overexpression of secretory Kex2p, were from Dr. R. Fuller
(University of Michigan, Ann Arbor, MI). pLS1-10, a plasmid for replace-
ment of the HindIII-XbaI region of 
 
PEP4
 
 with 
 
TRP1
 
 (
 
pep4::TRP1
 
) was
from Dr. A. Cooper (University of Missouri at Kansas City, Kansas City,
MO); the plasmid was cut with SacI and XhoI before integration/disrup-
tion. The H90T mutant in ICFP (mutation of His5 of the insulin B-chain)
was made by a 369-bp EcoRI-HindIII PCR-amplified fragment containing
the relevant CAC(His)
 
→
 
ACC (Thr) mutation, which was used to replace
the matching EcoRI-HindIII fragment of ICFP in pYES2.
 
Filter Blot Assays
 
To detect secretion of insulin or its precursor (defined as “immunoreac-
tive insulin secretion”), colonies or patches were replica plated onto nitro-
cellulose filters placed on top of plates containing 2% galactose as the sole
carbon source. After 24–40 h, cells were washed off the filter with PBS
plus 0.1% Tween-20. The filter was then incubated with a 1:500 dilution of
guinea pig antiinsulin serum (Linco Research) followed by peroxidase-
conjugated goat anti–guinea pig secondary (1:2,500; Jackson ImmunoRe-
search Laboratories) and finally detected by ECL. To detect CPY secretion
after overnight growth of the cells, the filter was incubated sequen-
tially with a 1:4,000 dilution of mouse monoclonal anti-CPY (Molecular
Probes) and a peroxidase-conjugated goat anti–mouse secondary anti-
body (1:3,000; Bio-Rad Laboratories).
 
Metabolic Labeling and Immunoprecipitation
 
Cells were grown to exponential phase in minimal medium supplemented
with required amino acids but without methionine and cysteine using ei-
ther 2% galactose or 2% glucose as appropriate and then sedimented at
3,000 
 
g
 
 for 5 min and resuspended at 4 OD
 
600
 
/ml in the same medium plus
1 mg/ml BSA. Insulin contains six cysteine residues and the 
 
 
 
-leader pep-
tide contains one methionine. For pulse labeling, [
 
35
 
S]cysteine (NEN Life
Science Products) was added at 50 
 
 
 
Ci per OD
 
600
 
 for the times indicated.
For chase, the cells were sedimented and resuspended in synthetic com-
plete (SC) medium plus 10 mM methionine and cysteine. At various chase
times, 1-ml aliquots were transferred to ice, and 10 mM sodium azide and
a protease inhibitor cocktail (0.25 
 
 
 
g/ml aprotinin, 0.1 mM leupeptin, 10 
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M pepstatin, 5 mM EDTA, 10 
 
 
 
M E64, 1 mM DFP, 0.02% BSA) were
added immediately. Cells were then sedimented at 3,000 
 
g 
 
for 5 min, and
the supernate-containing secreted proteins were collected for further
analysis. The cells were resuspended in 100 
 
 
 
l breaking buffer containing
6 M urea, 1% SDS, 1 mM EDTA, 50 mM Tris, pH 7.5. In Fig. 10 B, urea
and SDS were replaced by 1% NP-40 in the breaking buffer. The cells
were lysed by vortexing with glass beads and then boiling for 4 min (al-
though in Fig. 10 B the boiling step was omitted). Samples were diluted
10-fold to a final concentration of 1% Triton X-100, 150 mM NaCl, 5 mM
EDTA, 50 mM Tris, pH 7.5, debris was pelleted in a microcentrifuge, and
immunoprecipitations were normalized to acid precipitable counts per
minute. Samples were precleared with 20 
 
 
 
l Zysorbin for 30 min (Zymed
Laboratories). Media and cell lysates were then immunoprecipitated with
10 
 
 
 
l guinea pig antiinsulin using 20 
 
 
 
l Zysorbin as a secondary immu-
noadsorbent. Immunoprecipitates were routinely digested with PNGase F
(New England Biolabs, Inc.) and analyzed by tricine-urea–SDS-PAGE
(Schagger and von Jagow, 1987), fluorography or PhosphorImaging, and
quantitation using ImageQuant software (Molecular Dynamics).
 
Genetic Screen
 
L5145/pMI316 cells bearing integrated 
 
GAL1-ICFP
 
 were transformed
with a mutagenized yeast genomic library with random insertions of 
 
lacZ/
LEU2
 
 (Burns et al., 1994). Leu
 
 
 
 transformants were replica plated to ni-
trocellulose filters atop plates containing 2% galactose as the sole carbon
source. Filter blot assays for immunoreactive insulin secretion were per-
formed as described above. Out of 90,000 transformants screened, 31 colo-
nies were picked that displayed enhanced immunoreactive insulin secre-
tion (eis) over the untransformed parental strain. After patching and
rescreening, 24 of these were reconfirmed. After backcross to the parental
ICFP-containing strain followed by sporulation and tetrad analysis, nine
of these colonies showed a 2:2 distribution of eis linked to the LEU2 inser-
tion, indicating single gene disruption. These clones were designated se-
quentially 
 
eis1
 
 to 
 
eis9
 
. After transformation with pRSQ, the disrupted
genes were recovered as plasmid DNA (Burns et al., 1994). The identity
of disrupted 
 
eis
 
 genes was determined by sequencing genomic DNA adja-
cent to the insertion.
 
Indirect Immunofluorescence
 
Indirect immunofluorescence was performed as described (Preuss et al.,
1991) with the following modifications. In brief, cells growing exponen-
tially in 2% galactose-containing medium were fixed with 4% formalde-
hyde in 0.1 M potassium phosphate, pH 6.5. Cells were spheroplasted with
oxalyticase (Enzogenetics) and permeabilized briefly with methanol and
acetone. Cells were then incubated overnight with antiinsulin at 1:500 fol-
lowed by a Cy3-conjugated secondary antibody (Jackson ImmunoRe-
search Laboratories). Cells were viewed with an Olympus IX70 micro-
scope; images were collected digitally and analyzed using Adobe
Photoshop
 
®
 
 software.
 
Sucrose Gradient and DTT Accessibility Assays
 
For in vitro analyses of intracellular ICFP and insulin, cells expressing
ICFP from the 
 
GPD1
 
 promoter were employed. Cells were labeled as de-
 
scribed above. For sucrose gradient analysis, cells were lysed with glass
beads in a buffer containing 50 mM NaCl, 2 mM ZnSO
 
4
 
, 2 mM CaCl
 
2
 
, and
25 mM MES, pH 5.0. The cell lysate (2 ml) was then loaded onto a discon-
tinuous sucrose gradient comprised of 2 ml each of 15 and 30% sucrose in
the same buffer. The velocity gradients were centrifuged at 100,000 
 
g
 
av
 
 for
90 min. Gradient collection was simplified to two fractions comprising the
upper half (including all of the load and the upper half of the 15% sucrose
layer) and the lower half (including the lower half of the 15% sucrose
layer and all of the 30% sucrose layer). From equal aliquots of each half,
sucrose was diluted and the samples were immunoprecipitated with an an-
tiinsulin antibody. Immunoprecipitates were analyzed by SDS-PAGE and
fluorography.
The disulfide accessibility assay was modified from Huang and Arvan
(1995). In brief, cells were lysed and immunoprecipitated in a buffer con-
taining 170 mM NaCl, 5 mM EDTA, 1% Triton X-100, 50 mM Tris, pH
7.5. The insulin immunoprecipitates were washed once in a buffer contain-
ing 150 mM NaCl, 2 mM EDTA, 1% NP-40, 1% sodium deoxycholate, 10
mM Tris, pH 7.5. After a brief water wash, parallel samples were either
employed as untreated controls or treated first with 20 mM DTT in water
at 37
 
 
 
C for 30 min followed by incubation with 29 mM iodoacetamide.
Subsequently, all samples were incubated with 1,000 U of endoglycosidase
H at 37
 
 
 
C for 1 h. Samples to be used as untreated controls were boiled in
SDS-gel sample buffer in the presence or absence of 20 mM DTT and fi-
nally incubated at 37
 
 
 
C for 30 min in the presence of 41 mM iodoaceta-
mide before gel loading. The experimental sample was not further treated
with DTT but brought to 41 mM iodoacetamide and incubated at 37
 
 
 
C for
30 min before boiling in SDS-gel sample buffer.
 
Results
 
Insulin Undergoes Retention and Degradation 
in the Yeast Secretory Pathway
 
The ICFP cDNA was constructed as a chimera encoding
the signal and leader peptides of prepro-
 
 
 
 factor fused via
a single dibasic (KR) cleavage site to a polypeptide in
which the B chain (first 29 residues) and A chain of insulin
are made contiguous by an alanine-alanine-lysine linker
(Fig. 1 A). (For simplicity in this paper, we refer to this
single chain insulin simply as insulin or mature insulin in
reference to its endoproteolytic liberation from the ICFP
precursor.) When ICFP driven by a 
 
GAL1
 
 promoter (Fig.
1 A) was expressed as a single copy integrated in the ge-
nome (YIp), secretion of immunoreactive insulin (defined
as secretion of protein blotable with antiinsulin antibody;
described in Materials and Methods) was at the lower lim-
its of detection when yeast were grown on galactose as the
sole carbon source (Fig. 1 B). To examine further the ex-
pression of ICFP, cells were pulse labeled with [
 
35
 
S]cys-
teine for 1 min followed by immediate lysis, insulin im-
 
Table I. Strains Used in This Study
 
L5145*
 
MAT
 
 
 
 kss1 ura3-52 leu2-3, 112 his3 trp1^63 ade2 GAL+
L5141* MAT  kss1 ura3-52 leu2-3, 112 his3 trp1^63 ade2 GAL+
PA13‡ MAT  kss1 ura3-52 leu2-3, 112 his3 trp1^63 ade2 GAL+ pep4 ::URA3
DI3G‡ MAT  kss1 ura3-52 leu2-3, 112 his3 trp1^63 ade2 GAL+ pep4 ::URA3 vps35::LEU2
YB108‡ MAT  kss1 ura3-52 leu2-3, 112 his3 trp1^63 ade2 GAL+ pep4 ::TRP1 vps35::LEU2
DI4E‡ MAT  kss1 ura3-52 leu2-3, 112 his3 trp1^63 ade2 GAL+  pep4 ::URA3 vps13::LEU2
DIV3H‡ MAT  kss1 ura3-52 leu2-3, 112 his3 trp1^63 ade2 GAL+ pep4 ::URA3 vps4::LEU2
DVI4A‡ MAT  kss1 ura3-52 leu2-3, 112 his3 trp1^63 ade2 GAL+ pep4 ::URA3 vps8::LEU2
DVIII1C‡ MAT  kss1 ura3-52 leu2-3, 112 his3 trp1^63 ade2 GAL+ pep4 ::URA3 vps36::LEU2
PA11D‡ MAT  kss1 ura3-52 leu2-3, 112 his3 trp1^63 ade2 GAL+ pep4 ::URA3 vps10::LEU2
YB96‡ MAT  kss1 ura3-52 leu2-3, 112 his3 trp1^63 ade2 GAL+ pep4 ::URA3 kex2::HIS3
TBY102§ MAT  ura3-52 leu2-3, 112 his3-D200 trp1- 901 lys2-801 suc2- 9 sec18-1 GAL+
*As described in Materials and Methods.
‡This study.
§Brigance et al., 2000. The Journal of Cell Biology, Volume 153, 2001 1190
munoprecipitation, deglycosylation of the  -leader with
PNGase F, and analysis by tricine-urea–SDS-PAGE.
(Note that all cysteine residues are conserved between
ICFP and mature insulin.) In this case, an intracellular
ICFP band migrating at Mr   14 kD was observed (Fig. 2
A, left lane). In a parallel sample that was labeled for 5
min (Fig. 2 A, right lane), a second smaller band was pro-
duced that comigrated with an authentic insulin standard.
These data suggested that ICFP may undergo relatively
rapid proteolytic processing to mature insulin (described
further below).
To understand the poor secretion of immunoreactive in-
sulin, cells expressing ICFP on a centromeric plasmid were
pulse labeled for 10 min and then either lysed or chased
for 30 min. Although both ICFP and single chain insulin
bands were detected intracellularly immediately after
pulse labeling (Fig. 2 B, left lane), secretion of radiola-
beled ICFP or processed insulin at 30 min was virtually un-
detectable (Fig. 2 B, right lane). Moreover, after a 30-min
chase essentially no immunoprecipitable forms remained
intracellularly (Fig. 2 B, middle lane), suggesting relatively
rapid intracellular degradation.
Gene Disruptions That Enhance Immunoreactive 
Insulin Secretion
The foregoing results suggested some form of quality con-
trol of insulin secretion. To examine this further, a genetic
approach was undertaken. Using yeast expressing ICFP
from a single copy integrated in the genome (see Fig. 1 B)
and a mutagenized genomic library containing random in-
sertions of lacZ and LEU2 (Burns et al., 1994), 90,000
transformants were screened by the Western blot assay to
yield nine eis mutants displaying enhanced immunoreac-
tive insulin secretion (as described in Materials and Meth-
ods). The nine eis mutants corresponded to six distinct
gene disruptions, five of which were identified as VPS35,
VPS13, VPS4, VPS8, and VPS36. These genes have been
shown previously to regulate trafficking in the Golgi↔en-
dosome↔vacuole pathway (Stack and Emr, 1993; Bryant
and Stevens, 1998). vps35 and vps8 appeared to produce
the greatest enhancement of immunoreactive insulin se-
cretion,  vps4 and vps13 produced an intermediate en-
hancement, and vps36 produced only a slight increase
(Fig. 3 A).
Most ICFP Advances through the Golgi Complex 
into the Endosomal/Vacuolar System
Even though enhanced immunoreactive insulin secretion
was observed in several vps mutants acting in the distal
secretory pathway, ER to Golgi transport is known to be a
rate-limiting step in the trafficking of chimeras containing
the prepro-  leader (Elliott et al., 1989). We therefore em-
ployed a standard assay (Finger et al., 1993; Loayza et al.,
1998) to examine whether ICFP is subject to ERAD. The
ICFP was expressed in a sec18 strain in which traffic to the
Golgi complex is blocked at the nonpermissive tempera-
ture. After shifting to 37 C, cells were pulse labeled, lysed
at varying times of chase  1.5 h, and analyzed by immuno-
precipitation with antiinsulin, PNGase F digestion, and
tricine-urea–SDS-PAGE. Strikingly, no endoproteolytic
processing of ICFP was observed in the sec18 background
(Fig. 4, A and B) in contrast to wild-type yeast (see Fig. 2
A). Furthermore, unlike what has been observed for
ERAD substrates (Plemper and Wolf, 1999) the ICFP
molecule was completely stable throughout the 90-min
time course. Thus, no evidence was obtained for ERAD of
the insulin-containing chimera.
Figure 1. (A) Structure and expression of the ICFP. (B) Yeast expressing ICFP either in single copy (YIp), low copy (CEN plasmid), or
high copy (2   plasmid) were grown as patches and replica plated onto nitrocellulose filters atop galactose-containing plates. After 40 h,
the filters were washed to remove cells and immunoblotted with antiinsulin antibody and a peroxidase-conjugated secondary antibody.
Figure 2. In wild-type yeast, ICFP is processed to single chain
insulin but is not secreted efficiently. (A) Yeast expressing ICFP
driven by a GAL1 promoter on a high copy plasmid were pulse
labeled with [35S]cysteine for the times indicated without further
chase. (Note that in this strain the GAL1 promoter is not particu-
larly strong.) Cells were lysed and insulin immunoprecipitated
and digested with PNGaseF before nonreducing SDS-PAGE.
Note that the initially synthesized precursor is  14 kD, which is
processed to an  5-kD band comigrating with authentic insulin
(INS). (B) Yeast expressing ICFP driven by a GAL1 promoter
on a low copy (CEN) plasmid were pulse labeled for 10 min with
[35S]cysteine and either lysed or chased for a further 30 min in
complete medium. Note that after chase, insulin-immunoprecipi-
table bands are undetectable in either the medium or cell lysate.
C, cells; M, medium.Zhang et al. Insulin Processing and Sorting in Yeast 1191
We next tested directly whether immunoreactive insulin
was degraded in the endosomal/vacuolar system by exam-
ining ICFP expression in a pep4  strain (deficient for vac-
uolar protease activity) (Ammerer et al., 1986). In this
case, fully processed intracellular insulin was stabilized
dramatically, although no increase in insulin secretion was
observed (Fig. 4 C). Indeed, insulin clearly accumulated in
the vacuole (identified under Nomarski optics) as judged
by indirect immunofluorescence in pep4  cells (Fig. 5, top
panels). Furthermore, in an eis5/vps4 pep4 double mutant
(known to accumulate an enlarged prevacuolar compart-
ment [Bryant and Stevens, 1998]) staining was concen-
trated in a bright spot next to the vacuole (Fig. 5, bottom
panels), indicating accumulation in the prevacuolar com-
partment. These data prove that immunoreactive insulin is
retained intracellularly by trafficking from the Golgi com-
plex through the endosomal system to the vacuole.
Is Vps10p the Insulin Sorting Receptor?
Several groups have described previously the yeast Golgi
complex as a regulatory site from which foreign, mutant,
or even wild-type versions of certain yeast proteins may be
recognized for delivery to the endosomal/vacuolar system
(Hong et al., 1996; Luo and Chang, 1997; Roberg et al.,
1997; Li et al., 1999; Liu and Culotta, 1999). In at least
some of these cases, the recognition and/or targeting ma-
chinery appears to be saturable upon substrate overex-
pression (Hong et al., 1996). We tested whether insulin de-
livery to the endosomal/vacuolar system was saturable by
expressing ICFP at low copy on a centromeric plasmid
(CEN) or at high copy on a 2-  plasmid. Indeed, higher
immunoreactive insulin secretion was observed in a dos-
age-dependent manner (Fig. 1 C). Even greater secretion
was observed when ICFP expression was driven by the
strong constitutive GPD1 promoter (see below).
In addition to its receptor function in sorting of vacuolar
proteases (Marcusson et al., 1994; Cooper and Stevens,
1996), Vps10p has been proposed to function as a Golgi-
based sorting receptor for targeting misfolded secretory
proteins to the endosomal system for vacuolar degrada-
tion (Hong et al., 1996; Durr et al., 1998; Holkeri and
Makarow, 1998; Jorgensen et al., 1999). To test whether
Vps10p plays a role in preventing immunoreactive insulin
secretion, Western blot assays were used to compare the
secretion of immunoreactive insulin and CPY in a vps10-
null mutant versus the eis/vps mutants. As shown in the
bottom panel of Fig. 3 B, all of the vps mutants exhibited
Figure 3. Identification and charac-
terization of eis mutants that yield en-
hanced insulin secretion. (A) Filter
blot assay for immunoreactive insulin
secretion from the nine colonies ob-
tained by genetic screening, which rep-
resent disruptions of six independent
genes. Five of these proved to be genes
in the vps pathway as indicated. (B)
Five eis/vps mutants and a vps10-null
mutant were replica plated and tested
by filter blot assay for immunoreactive insulin secretion (top panel) and CPY secretion (bottom panel). Note that like the eis/vps mu-
tants obtained by genetic screen vps10 dramatically increases CPY secretion, but the effect on ICFP secretion is minimal.
Figure 4. The ICFP is not subject to ERAD but is subject to degradation by vacuolar proteases. (A) The ICFP was expressed from the
GPD1 promoter in a sec18-1 mutant strain where the ICFP cannot reach the Golgi complex. Cells were preincubated at the restrictive
temperature (37 C) for 10 min and labeled for 5 min. Cells were chased for the times indicated, lysed, and immunoprecipitated with an-
tiinsulin and digested with PNGase F before SDS-PAGE. (B) Quantification by densitometry of the results shown in A. (C) The ICFP
was expressed in a pep4-null strain. The cells were labeled and chased as in the legend to Fig. 2 B before insulin immunoprecipitation
and digestion with PNGaseF followed by SDS-PAGE and fluorography. Note that in a sec18 strain intracellular ICFP persists, whereas
in a pep4 strain intracellular insulin accumulates.The Journal of Cell Biology, Volume 153, 2001 1192
markedly enhanced immunoreactive CPY secretion, and
vps10 arguably yielded the strongest CPY secretion phe-
notype. However, enhanced immunoreactive insulin se-
cretion for vps10 was less than that seen with any other vps
mutants tested (Fig. 3 B, top panel).
A quantitative analysis of immunoreactive insulin secre-
tion from vps mutants was then performed by following
[35S]cysteine-labeled protein. First, the effect of each of
the five eis/vps mutations and vps10 was examined in
strains where ICFP expression was driven by a GAL1 pro-
moter on a centromeric plasmid. To improve intracellular
recovery, a pep4 mutation was introduced into each strain.
As shown in Fig. 6, each vps mutant tested showed an in-
crease in secretion of protein immunoprecipitable with an-
tinsulin. Quantitation of the data showed that whereas the
control strain secreted only  8% of the total, the vps36,
vps4, vps13, vps8, and vps35 strains secreted  19,  26,
 41,   55, and  76%, respectively. The vps10 strain
showed the lowest level of enhancement over the control,
secreting labeled insulin at a level approaching that of
vps36 ( 19%).
To quantify the saturability of endosome/vacuole deliv-
ery, identical pulse–chase experiments were performed in
which ICFP expression was driven by the GPD1 promoter
(which increases ICFP expression 5–10-fold in this strain
background; data shown below). This maneuver resulted
in an increase in the fractional secretion of protein immu-
noprecipitable with antiinsulin ( 36%). In addition, an as-
sortment of vps mutants showed a further increase in frac-
tional secretion (vps4,  47; vps1,  53; vps8,  57; vps13,
 64; vps35,  79%). The one exception was vps10, which
showed no further increase in fractional secretion (mea-
sured at  27%). Together, these data are inconsistent with
a central role of Vps10p as a sorting receptor for ICFP tar-
geting from the Golgi complex to the endosomal system.
Kex2p Is a Saturable Component Conferring 
Intracellular Retention of Insulin
The observations of proteolytic maturation of ICFP to a
form comigrating with authentic insulin (Fig. 2 A and Fig. 4
C) and blockade of this processing in a sec18 mutant (Fig.
4, A and B) are consistent with the notion that cleavage of
ICFP in the Golgi complex is catalyzed by the yeast en-
doprotease, Kex2p (Fuller et al., 1989). Additionally, a
striking finding in most of the vps mutants tested was that
increased fractional secretion of protein immunoprecipita-
ble with antiinsulin was comprised primarily of unproc-
essed ICFP. Although these findings are an expected side
effect of perturbed Kex2p cycling between Golgi and endo-
some in vps mutants (Bryant and Stevens, 1998), we noted
that increased ICFP secretion as a consequence of simple
overexpression (in the absence of VPS mutations) was also
enriched in unprocessed precursor (described further be-
low). These findings raised the possibility that Kex2p itself
might be a limiting factor required for insulin sorting.
Therefore, we reexamined ICFP expression (driven
from a GAL1 promoter on a centromeric plasmid) in a
kex2 pep4 strain. As demonstrated before, in the presence
of wild-type levels of Kex2p, virtually all ICFP was pro-
cessed to single chain insulin, and only a small fraction
( 10%) was secreted (Fig. 7, left). However, in the ab-
sence of Kex2p not only was there no ICFP cleavage, but
the protein was near quantitatively rerouted to the me-
dium (Fig. 7, right).
Figure 5. Indirect immunofluores-
cence localization of insulin in a pep4
strain and a vps4 pep4 double mutant.
Note that insulin accumulates in the vac-
uole in a pep4  mutant and in the pre-
vacuolar compartment in the class E vps
mutant. Cells were fixed, permeabilized,
and insulin labeled with antiinsulin and
a Cy3-conjugated secondary antibody.
Figure 6. Enhanced immunoreactive insulin secretion in various
eis/vps mutants is comprised largely of unprocessed ICFP. All
strains are pep4  mutants in order to stabilize the intracellular
protein. Cells were pulse labeled for 30 min and chased for 60
min. The cells and media underwent insulin immunoprecipitation
and digestion with PNGaseF before analysis by SDS-PAGE and
fluorography. Note that secretion of unprocessed ICFP was not
detected in the control strain or in a vps10 mutant.Zhang et al. Insulin Processing and Sorting in Yeast 1193
Secretion of Unprocessed ICFP Does Not Involve a 
Dominant Secretion Signal in the  -Leader Peptide
All evidence to date indicates that luminal protein target-
ing from the Golgi complex to the endosomal/vacuolar
system requires specific signal recognition, and loss of this
sorting results in protein secretion (Marcusson et al.,
1994). Nevertheless, we wished to formally exclude the
possibility that ICFP secretion might be mediated by a
dominant secretion signal in the  -leader peptide and that
loss of this signal upon endoproteolytic cleavage might
cause single chain insulin to be delivered to the vacuole.
Because published evidence indicates that a fragment of
the leader peptide from the secretory protein Hsp150 does
not contain a dominant secretion signal (Holkeri and
Makarow, 1998), we replaced the  -leader with this frag-
ment fused to single chain insulin (as described in Materi-
als and Methods). This new insulin-containing chimera
was quantitatively secreted (Fig. 8), indicating that secre-
tion of the unprocessed ICFP does not require specific
sorting information contained within the  -leader peptide.
Thus, intracellular retention of mature insulin cannot be
explained by endoproteolytic removal of a dominant se-
cretion signal.
Is Kex2p the Insulin Sorting Receptor?
Our screen for EIS genes did not yield any candidate sort-
ing receptors for insulin because none encoded a protein
bearing a luminal domain. However, like the Vps10p sort-
ing receptor Kex2p follows a generally similar itinerary in
which it is delivered to the endosomal system before recy-
cling back to the Golgi complex (Brickner and Fuller,
1997). Moreover, it has been hypothesized recently in
mammalian cells that proteases in the secretory pathway
might have the potential to perform double duty as non-
catalytic sorting receptors (Cool et al., 1997; Cool and
Loh, 1998; Normant and Loh, 1998). Therefore, it was im-
portant to test a possible role for Kex2p as a sorting recep-
tor for insulin.
Trafficking of Kex2p from the Golgi complex into the
endosomal system requires specific information included
in the COOH-terminal region of the protein: a COOH-
terminal deletion removing the serine/threonine-rich do-
main, the transmembrane domain, and the cytosolic tail
domain results in a truncated Kex2p, which is catalytically
active but behaves as a secretory protein, traveling quanti-
tatively from the Golgi to the cell surface (Brenner and
Fuller, 1992). Consequently, this secretory Kex2p cannot
function as a sorting receptor to convey ligands from the
Golgi to the endosomal system. Therefore, we tested ICFP
secretion in a kex2 pep4 strain expressing secretory Kex2p.
Confirming previous work, secretory Kex2p was massively
secreted (Fig. 9 A). Loss of Kex2p expression resulted in
nearly quantitative ICFP secretion when its expression
was driven from a GAL1 promoter (Fig. 9 B, middle two
lanes). Importantly, however, expression of secretory
Kex2p restored both endoproteolytic processing and intra-
cellular retention of insulin (Fig. 9 B, right two lanes).
When the GPD1 promoter was used to further overex-
press ICFP in excess of the ability of secretory Kex2p to
cleave it, the fractional secretion of protein immunopre-
cipitable with antiinsulin was markedly increased, and all
of the increase was comprised of unprocessed precursor
(Fig. 9, C compared with B). Moreover, endoproteolytic
processing of ICFP (expressed from a GAL1 promoter) by
secretory Kex2p also restored intracellular insulin reten-
tion in vps35 cells (Fig. 9 D). These findings confirm that
(a) Kex2p is a specific saturable component responsible
for intracellular insulin retention, and (b) Kex2p acts cata-
lytically as an endoprotease rather than as a luminal sort-
ing receptor for insulin trafficking.
Endoproteolytic Processing of ICFP Causes a Change 
in the Biophysical Properties of the Insulin Moiety
In mammalian   cells, endoproteolytic processing to gen-
erate insulin results in polymerization and intracellular re-
tention (Kuliawat and Arvan, 1994; Kuliawat et al., 2000).
To examine the biophysical state of insulin retained in
yeast cells, we modified two assays developed originally
for mammalian insulin. Multimeric insulin recovered from
pancreatic    cells has been detected by rapid sedimen-
tation upon sucrose velocity gradient centrifugation (Mi-
chael et al., 1987). Although this sedimentation in vitro is
not particularly quantitative, it nevertheless represents a
feature that is not shared by the insulin precursor (Kulia-
Figure 7. Deletion of
KEX2 causes near quantita-
tive rerouting of ICFP to the
medium. The strains are
pep4  mutants in order to
stabilize the intracellular
protein. Cells were pulse la-
beled for 30 min and chased
for 60 min. The lysed cells
and media underwent insulin immunoprecipitation and digestion
with PNGaseF before analysis by SDS-PAGE and fluorography.
Figure 8. Secretion of immunoreactive insulin is not mediated
by a dominant sorting signal in the  -leader. In this case, the
 -leader peptide in ICFP has been replaced by a fragment of the
HSP150 leader (as described in Materials and Methods). The
strains are pep4  mutants in order to stabilize the intracellular
protein. Cells were pulse labeled for 30 min and chased for 60
min. The lysed cells and media underwent insulin immunoprecip-
itation before analysis by SDS-PAGE and fluorography.The Journal of Cell Biology, Volume 153, 2001 1194
wat and Arvan, 1994). A second approach detects multi-
meric assembly of mammalian insulin as measured by a loss
of accessibility of its disulfide bonds to reduction by DTT
under nondenaturing conditions (Huang and Arvan, 1995).
Single chain insulin was examined from pep4 mutant
cells expressing ICFP under control of the strong GPD1
promoter. Cells were labeled continuously with [35S]cys-
teine for 45 or 60 min; under these conditions, significant
amounts of labeled insulin and ICFP precursor coexist.
First, we found, using a simplified sucrose velocity gradi-
ent (as described in Materials and Methods), that upon
processing to insulin about half of the mature molecules
exhibited very rapid sedimentation, which was not ob-
served for the ICFP itself (Fig. 10 A). Using a second as-
say, in the experiment shown in Fig. 10 B insulin immuno-
precipitates were resuspended and divided into various
aliquots. As a control, one aliquot was denatured in con-
ventional boiling SDS-containing gel sample buffer in the
presence of 20 mM DTT and then subsequently alkylated
with iodoacetamide. Denaturation allowed DTT to reduce
all disulfide bonds in both the unprocessed precursor and
mature insulin, causing a marked upward mobility shift for
both bands (Fig. 10 B, lane 1). For comparison, a second
aliquot was similarly denatured but without reduction, be-
ing alkylated only (Fig. 10 B, lane 2). A third aliquot was
tested for disulfide accessibility to 20 mM DTT under non-
denaturing conditions and then finally alkylated before
SDS-PAGE. As shown, mature insulin was extremely
resistant to reduction under nondenaturing conditions
(equals 5% reduced), reflecting an inaccessibility of disul-
fide bonds in its tertiary/quaternary structure, whereas ap-
proximately half of the insulin precursor was reduced
upon DTT exposure in the identical sample (Fig. 10 B,
lane 3). Thus, by two independent assays endoproteolytic
processing was associated with a significant change in the
biophysical properties of insulin.
The foregoing data raised the question of whether sort-
ing consequent to insulin precursor processing reflects any
established features of insulin assembly. It is known that
some key residues affecting insulin multimeric interactions
lie along the proximal (that is NH2-terminal) portion of
the insulin B chain. The B1–B8 sequence is notable for ex-
hibiting great conformational flexibility, interconverting in
a dynamic equilibrium between extended and more com-
pact ( -helical) configurations (Renscheidt et al., 1984;
Wollmer et al., 1989; Kadima et al., 1992); in particular,
the B5 histidine residues in the insulin hexamer play not
only an important local role in conformation of the proxi-
mal B chain (Bentley et al., 1976; Kim and Shields, 1992)
but also make structural contact in neighboring hexamers
Figure 9. Replacement of Kex2p by secretory Kex2p is sufficient to cause intracellular insulin retention. The strains are pep4  mu-
tants in order to stabilize the intracellular protein. Cells were pulse labeled for 30 min and chased for 60 min. (A) Chase media bathing
the indicated strains were collected and immunoprecipitated with an antibody against Kex2p. (B) Intracellularly retained and secreted
forms of immunoreactive insulin upon ICFP expression with a GAL1 promoter on a centromeric plasmid. Note that when truncated
secretory Kex2p is expressed in the kex2  mutant it alters protein targeting to the extent that insulin is made. (C) Intracellularly re-
tained and secreted forms of immunoreactive insulin upon ICFP expression with a GPD1 promoter on a centromeric plasmid. Note that
at the higher levels of ICFP expression ICFP endoproteolytic processing is incomplete and the unprocessed portion is secreted. (D) In-
tracellularly retained and secreted forms of immunoreactive insulin upon ICFP expression with a GAL1 promoter in vps35 cells. In
these cells as well, secretory Kex2p expression alters the protein targeting to the extent that insulin is made.
Figure 10. Structural maturation of
insulin upon Kex2p-mediated endopro-
teolysis. (A) Sucrose velocity gradient
centrifugation. (B) Disulfide accessibil-
ity of ICFP and mature insulin under
denaturing and nondenaturing condi-
tions. Note that in these experiments
all samples were exposed to PNGase F
(A) or endoglycosidase H (B) at the
end of the analysis. In the experiment
shown in B, the enzyme digestion was performed in the complete absence of a reducing agent. The positions of reduced ICFP and insu-
lin standards (ICFP-R and INS-R) and oxidized standards (ICFP-O and INS-O) are shown to the left of the panel.Zhang et al. Insulin Processing and Sorting in Yeast 1195
(Baker et al., 1988). Recently, it has been suggested that
mutation of B5H can cause structural perturbations in ad-
jacent hexamers, which may affect insulin packing in vivo
(Tang et al., 1999). Interestingly, examination of an H90T-
ICFP mutant in which the insulin B5H residue is replaced
by B5T showed that the majority of processed mutant in-
sulin was secreted rather than being retained intracellu-
larly (Fig. 11 A, open arrows).
The B5T mutation creates a potential NH2-linked gly-
cosylation site within insulin in addition to the NH2-
linked glycosylation sites that are actually used within the
 -leader peptide of ICFP. Notably, however, our studies
showed clearly that the B5T insulin is not glycosylated as
demonstrated by an identical SDS-PAGE mobility to that
of nonmutagenized insulin and a lack of effect of PNGase
F digestion (Fig. 11 A). Moreover, whereas the nonmu-
tagenized insulin exhibits multimeric assembly as judged
by sucrose velocity gradient centrifugation in vitro (Fig. 10
A and Fig. 11 B), the B5T mutant insulin was unable to
sediment from the upper to the lower half of a sucrose ve-
locity gradient (Fig. 11 B), supporting the notion that per-
turbation of insulin targeting in the secretory pathway is re-
lated to structural effects of the threonine mutation itself.
Together, these data suggest that intracellular retention of
insulin in yeast cells is dependent on insulin structural mat-
uration, which is remarkably similar to recent conclusions
about intracellular insulin retention in the regulated secre-
tory pathway of mammalian cells (Kuliawat and Arvan,
1994; Huang and Arvan, 1995; Kuliawat et al., 2000).
Discussion
It has been reported that improved secretion efficiency of
some insulin-containing chimeras can be achieved by re-
placing an  -leader peptide with synthetic leader se-
quences that alter ER residence time, suggesting that ER
quality control is an important feature of insulin secretion
in yeast (Kjeldsen et al., 1997). However, we have discov-
ered several additional features of the system not typical
of ER quality control. First, using the ICFP construct de-
scribed in Fig. 1 A, simple overexpression caused signifi-
cantly enhanced secretion of immunoreactive insulin (Fig.
1 C), suggesting that one or more saturable components in
the yeast secretory pathway limits insulin secretion. Sec-
ond, newly-synthesized ICFP, containing a single dibasic
cleavage site, was rapidly processed to a band comigrating
with authentic insulin (Fig. 2 A) in a manner dependent on
arrival in the Golgi complex (Fig. 4 A) and Kex2p activity
(Fig. 7). Third, a direct assay for ERAD (in a sec18 mu-
tant) showed ICFP to be completely stable over a 90-min
time course (Fig. 4, A and B), suggesting that it is not a
ready substrate for typical ubiquitin-mediated protea-
some-dependent proteolysis (Plemper and Wolf, 1999).
Fourth, in the absence of Pep4p (vacuolar proteinase A)
insulin accumulates not in the ER but in the vacuole (Fig.
4 C) where it is delivered via the endosomal system (Fig.
5). These novel features of ICFP and insulin sorting are
summarized in Fig. 12.
The targeting of insulin expressed from ICFP is decided
upon in the Golgi complex (Fig. 12). Initially we thought
that vacuolar targeting of insulin might be mediated by a
Golgi-based quality control system like that responsible for
the degradation of a mutant lambda repressor protein
fused to invertase (Hong et al., 1996) and a variety of other
proteins in the secretory pathway (Chang and Fink, 1995;
Luo and Chang, 1997; Beck et al., 1999; Li et al., 1999).
Certainly, routing of insulin to the vacuole via the endoso-
mal system provides a rationale for why five out of six eis
gene disruptions identified in our genetic screen are vps
mutants (Fig. 3 A) that impair post-Golgi trafficking of
CPY (Fig. 3 B) and other vacuole-bound proteins. Never-
theless, there appear to be significant differences in the
molecular mechanisms accounting for inefficient secretion
of ICFP versus that of other proteins subject to Golgi qual-
ity control. First, the vacuolar delivery of the lambda re-
pressor-containing fusion protein occurs primarily when
the sequence is mutated to induce misfolding. By contrast,
single chain insulin folds similarly to authentic insulin
(Thim et al., 1986; Hua et al., 1998; Kjeldsen et al., 1998),
and no mutations inducing misfolding have been intro-
duced. Furthermore, all three insulin disulfide bonds ap-
pear intact (data not shown), and the band comigrates by
nonreducing SDS-PAGE with authentic insulin. Indeed,
our current evidence suggest that the unsecreted single
chain insulin takes on quaternary structural features (Fig.
10) observed for authentic insulin, which are dependent on
a native tertiary structure (Kuliawat and Arvan, 1994;
Huang and Arvan, 1995). Second, although Vps10p has
been proposed to operate as a quality control receptor in
the Golgi complex for certain substrates (Hong et al., 1996;
Durr et al., 1998; Holkeri and Makarow, 1998; Jorgensen et
al., 1999), vps10 cells did not show significantly increased
secretion of ICFP (Fig. 3 B and Fig. 6). Thus, a Vps10p-
mediated mechanism does not appear to contribute signifi-
cantly to the sorting of insulin in the secretory pathway.
A novel aspect of the present studies was our discovery
that deletion of KEX2 causes quantitative secretion of
Figure 11. Intracellular retention of insulin is perturbed in a
point mutant changing the insulin B5 histidine to threonine. The
strains are pep4  mutants in order to stabilize the intracellular
protein. (A) Intracellularly retained and secreted insulin upon ex-
pression of the nonmutagenized ICFP control (Con) or the H90T-
ICFP mutant (B5T) with a GAL1 promoter on a centromeric
plasmid. Cells were pulse labeled for 30 min and chased for 60
min. The lysed cells and media underwent insulin immunoprecipi-
tation before analysis by SDS-PAGE and fluorography. Note the
dramatically increased secretion of the B5T mutant insulin (open
arrows). Where indicated, the samples were digested with PNGaseF
before SDS-PAGE. Only the insulin bands are shown in order to
facilitate direct comparison of insulin secretion efficiency. C, cells;
M, medium. (B) Intracellular nonmutagenized insulin control pro-
tein (Con) or the mutagenized insulin (B5T) followed by sucrose
velocity gradient centrifugation analysis as in the legend to Fig. 10
A. Note that sedimentation of the B5T mutant (arrow) is clearly in-
hibited. U, top half of gradient; L, bottom half of gradient.The Journal of Cell Biology, Volume 153, 2001 1196
ICFP (Fig. 7). We considered initially the possibility, albeit
unprecedented, that the  -leader peptide might contain a
dominant secretion signal, the loss of which would result in
intracellular insulin retention. This possibility was ex-
cluded from the results of experiments in which the  -leader
was replaced with a fragment of another leader peptide
known to lack a dominant secretion signal (Fig. 8). These
findings led us to consider a second hypothesis that Kex2p
itself might serve as a sorting receptor that causes intracel-
lular insulin retention. However, in either a kex2-null
strain (Fig. 9 B) or a vps35 strain (Fig. 9 D), expression of
secretory Kex2p is sufficient to cause intracellular insulin
retention even though secretory Kex2p itself is delivered
from the Golgi complex to the cell surface (Fig 9 A).
Moreover, the degree to which secretory Kex2p (or wild-
type Kex2p) conferred intracellular retention was limited
to the extent that the precursor protein was processed to
mature insulin (Fig. 9 C). This indicates that Kex2p enzy-
matic activity in the Golgi complex is a saturable limiting
component in the molecular sorting of the insulin precur-
sor (Fig. 12). Moreover, when ICFP is mutated to make
substitutions at the dibasic cleavage site, secretion of im-
munoreactive insulin (precursor) is also increased (our un-
published data). Altogether, our data indicate that it is en-
doproteolysis itself that prevents rapid secretion of the
insulin precursor (Fig. 12).
Although our data do not formally exclude the possibil-
ity of sorting receptors for processed insulin, no genes en-
coding proteins with a luminal domain (that could serve as
potential sorting receptors) were identified in our genetic
screen. The fact that kex2 was not isolated in the eis screen
may be accounted for by the fact that in our strain back-
ground, kex2 mutant cells seem to grow more slowly, and
the filter blot assay used for screening is indirectly depen-
dent on the size of the colonies secreting ICFP. Likewise,
other gene disruptions that adversely affect cell growth
would also be overlooked in the screen, and this conceiv-
ably could contribute to the fact that we did not recover a
potential sorting receptor.
We have proposed in mammalian-regulated secretory
cells that endoproteolytic conversion to insulin facilitates
intracellular retention of the newly synthesized protein
(Kuliawat et al., 2000). This may occur because homomul-
timerization limits the ability of insulin to enter post-Golgi
transport intermediates leading ultimately to the cell sur-
face (Kuliawat and Arvan, 1992). It seems quite possible
that related phenomena could account for insulin traffick-
ing in the secretory pathway of yeast cells. Our evidence
supports the idea that there is a change in biophysical
properties upon endoproteolytic conversion to the mature
insulin species (Fig. 10). Intriguingly, recent proposals for
mechanisms that alter post-Golgi targeting of other pro-
teins include homomultimerization facilitated by endopro-
teolytic cleavage at dibasic sites (Silletti et al., 2000) and
ordered luminal protein aggregation (Wolins et al., 1997).
Indeed, we find that upon endoproteolytic processing, a
B5T mutant insulin is no longer efficiently retained, the
majority being secreted instead (Fig. 11 A), and this is cor-
related with an inability of the protein to form a stable
multimeric assembly, as measured by sucrose gradient
centrifugation (Fig. 11 B). In conclusion, although the is-
sue remains unresolved of whether a Golgi/post-Golgi
membrane-associated receptor plays any role in intracellu-
lar insulin targeting, it would appear that precursor en-
doproteolysis unmasks information required for sorting by
retention for the vast majority of, if not all, insulin mole-
cules in the eukaryotic secretory pathway.
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